Table 1 Clinical information in training and validation groups
Characteristics | Training group (N = 343) | Testing group (N = 221) | ||
|---|---|---|---|---|
High risk | Low risk | High risk | Low risk | |
Age | ||||
 <60 | 78 | 79 | 119 | 59 |
 ≥ 60 | 93 | 93 | 23 | 20 |
Gender | ||||
 Male | 117 | 116 | 125 | 66 |
 Female | 54 | 56 | 17 | 13 |
ALT (>/<=50 U/L) | ||||
 high | – | – | 60 | 31 |
 low | – | – | 82 | 47 |
 Unknown |  |  | 0 | 1 |
Main Tumor Size (>/<=5 cm) | ||||
 Large | – | – | 57 | 23 |
 Small | – | – | 84 | 56 |
 Unknown | – | – | 1 | 0 |
Multinodular | ||||
 Y | – | – | 34 | 11 |
 N | – | – | 108 | 68 |
Cirrhosis | ||||
 Y | – | – | 133 | 70 |
 N | – | – | 9 | 9 |
 Unknown | – | – |  |  |
CLIP staging | ||||
 0 | – | – | 54 | 53 |
 1 | – | – | 47 | 27 |
 2 | – | – | 30 | 5 |
 3 | – | – | 7 | 2 |
 4 | – | – | 1 | 2 |
 5 | – | – | 1 | 0 |
 9 | – | – | 2 | 0 |
Grade | ||||
 G1 | 15 | 38 | – | – |
 G2 | 74 | 87 | – | – |
 G3 | 71 | 41 | – | – |
 G4 | 9 | 3 | – | – |
 Unknown | 2 | 3 | – | – |
TNM Stage | ||||
 T1 | 58 | 104 | 45 | 48 |
 T2 | 49 | 28 | 54 | 23 |
 T3 | 50 | 30 | 41 | 8 |
 T4 | 2 | 1 | 2 | 0 |
 Unknown | 12 | 9 |  |  |
T | ||||
 T1 | 61 | 107 | – | – |
 T2 | 55 | 29 | – | – |
 T3 | 46 | 29 | – | – |
 T4 | 9 | 4 | – | – |
 Unknown | 0 | 3 | – | – |
N | ||||
 N0 | 121 | 118 | – | – |
 N1 | 3 | 0 | – | – |
 Unknown | 47 | 54 | – | – |
M | ||||
 M0 | 125 | 120 | – | – |
 M1 | 2 | 1 | – | – |
 Unknown | 44 | 51 | – | – |
BCLC staging | ||||
 0 | – | – | 14 | 6 |
 1 | – | – | 84 | 64 |
 2 | – | – | 18 | 4 |
 3 | – | – | 24 | 5 |
 9 | – | – | 2 | 0 |
AFP (>/<=300 ng/ml) | ||||
 High | – | – | 70 | 30 |
 Low | – | – | 70 | 48 |
 Unknown | – | – | 2 | 1 |